References
- George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014 Nov;371(19):1847–1848.
- Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015 Sep;67(1):31–42.
- Cornec-Le Gall E, Delmas Y, De Parscau L, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis. 2014 Jan;63(1):119–123.
- Beck BB, van Spronsen F, Diepstra A, et al. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. Pediatr Nephrol. 2017 May;32(5):733–741.
- Claes KJ, Massart A, Collard L, et al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg. 2018 02;73(1):80–89.
- Marinozzi MC, Vergoz L, Rybkine T, et al. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014 Sep;25(9):2053–2065.
- Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010 Oct;5(10):1844–1859.
- Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014 Sep;124(11):1715–1726.
- Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017 01;40(1):21–48.
- Grangé S, Bekri S, Artaud-Macari E, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet. 2015 Sep;386(9997):1011–1012.
- Coppola A, Davi G, De Stefano V, et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost. 2000;26(3):243–254.
- van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Curr Hypertens Rep. 2003 Feb;5(1):26–31.
- Rodríguez-Esparragón F, Hernández-Perera O, Rodríguez-Pérez JC, et al. The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values. Clin Exp Hypertens. 2003 May;25(4):209–220.
- Lin PT, Cheng CH, Wei JC, et al. Low plasma pyridoxal 5ʹ-phosphate concentration and MTHFR 677C–>T genotypes are associated with increased risk of hypertension. Int J Vitam Nutr Res. 2008 Jan;78(1):33–40.
- Yin RX, Wu JZ, Liu WY, et al. Association of several lipid-related gene polymorphisms and blood pressure variation in the Bai Ku Yao population. Am J Hypertens. 2012 Aug;25(8):927–936.
- Nakata Y, Katsuya T, Takami S, et al. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens. 1998 Aug;11(8 Pt 1):1019–1023.
- Fowdar JY, Lason MV, Szvetko AL, et al. Investigation of homocysteine-pathway-related variants in essential hypertension. Int J Hypertens. 2012;2012:1–9.
- Goforth RL, Rennke H, Sethi S. Renal vascular sclerosis is associated with inherited thrombophilias. Kidney Int. 2006 Aug;70(4):743–750.